发明名称 |
IMMEDIATE RELEASE 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide FORMULATION |
摘要 |
A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed |
申请公布号 |
US2015320749(A1) |
申请公布日期 |
2015.11.12 |
申请号 |
US201414273874 |
申请日期 |
2014.05.09 |
申请人 |
Bhardwaj Upkar;Comfort Ann Reese;Li Ping;Li Shoufeng;Makarov Alexey;Bordawekar Mangesh Sadashiv |
发明人 |
Bhardwaj Upkar;Comfort Ann Reese;Li Ping;Li Shoufeng;Makarov Alexey;Bordawekar Mangesh Sadashiv |
分类号 |
A61K31/506;A61K9/28 |
主分类号 |
A61K31/506 |
代理机构 |
|
代理人 |
|
主权项 |
1. A solid dosage form comprising: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coats 7-13% of said core, wherein disintegration of said solid dosage form is delayed by 4-15 minutes. |
地址 |
Coram NY US |